California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-e
We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati
A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno
BioNTech has been thrust into the limelight with its mRNA-based vaccines and therapeutics – most notably its Pfizer-partnered COVID-19 shot – but the other side of its business is CAR-T the
Despite setbacks for projects trying to harness the power of the cytokine interleukin-2 (IL-2) as a cancer therapy, there are still plenty of players on the field – and Roche has just joine
